Cartilage Degeneration Market Expected to Reach US$ 14.7 Billion Globally in 2025


In human body cartilage covers the joints in bones and allows reduces the friction between bones during movements. Impairment of the cartilage is observed as a common type of injury triggered due to osteoarticular disease, accident, trauma and other physiological conditions. Cartilage Degeneration Market is expected to grow rapidly due to global rise in geriatric population, rise in obese population and increase in demand for minimally invasive surgical products. Additionally, increase in medical tourism in European & Asian countries are the key factors which likely to drive the growth of global cartilage degeneration market. Conversely, rise in cost of surgical devices, treatment and lack of satisfactory reimbursement policies are the factors which may restrain the growth of the market.

The global cartilage degeneration market is classified in to procedure type, application, and treatment delivery channels. By procedure type the market is categorized as Joint Replacements, Chondroplasty, Osteochondral Transplants, Micro-Fracture, Meniscus Transplants, Cell based Cartilage Resurfacing, Autologus Chondrocyte Implantation (ACI), Others. By application the market is divided in to knee, hips & others. By treatment delivery channels the market is classified as Hospitals, Academic & Research Institutes, Specialty Clinics, Ambulatory Surgical Centers, Others.

By procedure type, joint replacements accounted for the largest share of the market in 2016. The major reasons driving the growth of the segment are increase in industrial accidents, the number of road accidents, rise in sports injuries leading to severe cartilage damage and deformities. After joint replacements the chondroplasty segment accounted for the major share of the market in 2016. The key elements of this are growth are easy accessibility of the procedure in the hospitals, diagnostic centers. It also takes less time for recovery in comparison with other traditional methods of surgeries. Autologous chondrocyte implantation (ACI) is a comparatively new technology used for the treatment of isolated full-thickness articular cartilage imperfections of the knee.

By application the knee surgery or repair market is anticipated the market in near future. Knees are the largest joints in a human body. When a person’s knees are damaged by arthritis, injury, or any other trauma. Patients may even start to feel pain while lying down or sitting.  Nonsurgical treatments of knees such as medications and using support are opted by patients. But when these treatments are no longer effective, then patients may need to consider the alternative treatment of total knee replacement surgery. The number of people affected with knee osteoarthritis is expected to grow in the near future due to increasing aging population and rising rate of obesity/overweight among the general population. According to a report from Centers for Disease Control and Prevention in 2014, the prevalence of knee osteoarthritis in men was lower as compared to women. It also stated that about 13% of women and 10% of men aged 60 years and older have indicative knee osteoarthritis symptoms. After knee segment the market is dominated by hips and others respectively.

By treatment delivery channels the market was dominated by hospitals followed by specialty clinics. Some of the reasons of the rapid growth of these segments are increase in number of hospitals & growing government support for improving the health care sector, increasing demand for new test assays and rise in biomarker research.

The global cartilage degeneration market is fragmented, with leading players accounting for majority share of the market. The key competitors contributing to the global market growth include B. Braun Melsungen AG, DePuy Synthes, Smith & Nephew plc, Stryker Corporation, and Zimmer Biomet. Research on cartilage degeneration and other disease indications have provided a much needed breakthrough to pharmaceutical and biotechnology companies, driving a way forward to personalized health care and targeted therapies. Companies operating in this market are actively engaged in mergers and acquisitions. For example, in May 2016, Zimmer acquired Cayenne Medical. The acquisition is anticipated to enhance Zimmer Biomet’s Sports Medicines product portfolio.

Inquire to Know more about Cartilage Degeneration Market –

Leave a Reply